T0	Participants 59 121	previously untreated advanced esophagogastric cancer patients.
T1	Participants 382 507	patients within an open label, randomized clinical phase II trial with advanced or metastatic gastric/esophagogastric cancer.
T2	Participants 516 561	Previously untreated patients were randomized
T3	Participants 925 949	Of 118 patients enrolled
T4	Participants 1570 1625	levels in patients with advanced esophagogastric cancer